Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Immunic, Inc.NASDAQ: IMUX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $32.59M (cash outflow) rose 27.9% year over year, ahead of the +8.2% change in trailing-twelve-month net income. Sequentially, it rose 68.8% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$72.28M (-25.6%) for the fiscal year ending Dec 2026, a slowdown from the -3.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$32.59M+68.8% QoQ
- Last fiscal yearDec 2025
- -$97.17M-3.3% YoY
- LTMMar 2026
- -$104.29M+8.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.9% | +32.1% | +4.2 pp |
| 1 year | -3.3% | -25.6% | -22.3 pp |
| 3-year CAGR | -6.9% | -17.0% | -10.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (97.17M) USD
- Year-over-year change
- +3.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (97.17M) | +3.3% |
| FY2024 | 2024-12-31 | (100.51M) | -7.4% |
| FY2023 | 2023-12-31 | (93.61M) | +22.3% |
| FY2022 | 2022-12-31 | (120.41M) | -29.5% |
| FY2021 | 2021-12-31 | (92.95M) | — |
Net Income vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 net income of $104.29M is the 3rd largest of the 9 companies compared; the peer median is $77.81M.
- Its year-over-year change of +8.2% is the 3rd highest of 9, against a peer median of -7.5%.
- Over three fiscal years its annual growth of -6.9% compares with a peer median of +18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| Peer median (excluding IMUX) | $77.81M | -7.5% | +18.7% | 1360.6% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| Deferred Income Tax | 4.33M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.95M | 7.93M | 7.1M | 8.53M | 8.86M |
| Change in Working Capital | (9.28M) | 9.53M | 15.05M | 564K | 1.84M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 176K | 799K | 817K | 3.15M | 1.24M |
| Other Working Capital | (9.46M) | 8.73M | 14.23M | (2.58M) | 601K |
| Other Non-Cash Items | 8.63M | 37.73M | 523K | 6.52M | 497K |
| Operating Cash Flow | (83.23M) | (65.14M) | (70.83M) | (84.77M) | (85.81M) |
| Capital Expenditures | (67K) | (112K) | (334K) | (264K) | (161K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (9.63M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 9.8M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (67K) | (9.74M) | 9.46M | (264K) | (161K) |
| Debt Repayment | 0 | 0 | 0 | 74.27M | 0 |
| Common Stock Issued | 42.75M | 39.58M | 853K | 191K | 65.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 92K | 187K | 180K | 77K | 0 |
| Financing Cash Flow | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M |
| Effect of Forex Changes | (130K) | (993K) | 262K | (517K) | 205K |
| Net Change in Cash | (40.59M) | 19.88M | (60.07M) | (11.01M) | (20.19M) |
| Free Cash Flow | (83.3M) | (65.26M) | (71.16M) | (85.03M) | (85.97M) |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.